Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Abstract Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retent...

Full description

Bibliographic Details
Main Authors: Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H. Chang, Yu Hu, Heng Mei
Format: Article
Language:English
Published: Nature Publishing Group 2023-04-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00822-w

Internet

https://doi.org/10.1038/s41408-023-00822-w

Similar Items